Adage Capital Partners
BHVN

Adage Capital Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Adage Capital Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,308,014
Closed -$349M – 1140
2022
Q3 		$349M Sell
2,308,014
-731,078
-24% -$108M 0.87% 10
2022
Q2 		$443M Buy
3,039,092
+2,849,092
+1,500% +$364M 1.02% 11
2022
Q1 		$22.5M Buy
190,000
+75,000
+65% +$9.35M 0.04% 420
2021
Q4 		$15.8M Buy
115,000
+55,000
+92% +$6.99M 0.03% 559
2021
Q3 		$8.34M Buy
+60,000
New +$7.49M 0.02% 746
2021
Q2 		– Sell
-70,000
Closed -$4.79M – 1170
2021
Q1 		$4.79M Sell
70,000
-80,000
-53% -$6.47M 0.01% 804
2020
Q4 		$12.9M Sell
150,000
-300,000
-67% -$25.4M 0.03% 534
2020
Q3 		$29.3M Buy
450,000
+250,000
+125% +$16.4M 0.07% 283
2020
Q2 		$14.6M Buy
200,000
+3,025
+2% +$161K 0.04% 463
2020
Q1 		$6.7M Sell
196,975
-703,025
-78% -$32.1M 0.02% 536
2019
Q4 		$49M Sell
900,000
-675,000
-43% -$33.4M 0.12% 207
2019
Q3 		$65.7M Buy
1,575,000
+300,000
+24% +$12.7M 0.16% 160
2019
Q2 		$55.8M Buy
1,275,000
+600,000
+89% +$33.8M 0.14% 192
2019
Q1 		$34.7M Buy
675,000
+175,000
+35% +$7.56M 0.09% 267
2018
Q4 		$18.5M Buy
+500,000
New +$18M 0.05% 355

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Adage Capital Partners's BHVN Position: Q4 2022 in Review

Adage Capital Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,308,014 shares — an estimated $349M sold.

Adage Capital Partners first reported a position in BHVN in Q4 2018 and held it in 15 quarters. The position peaked at $443M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Adage Capital Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Adage Capital Partners sold 2,308,014 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $349M.
  • Adage Capital Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 15 quarters.
  • Adage Capital Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $443M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.